sbi-087
mAbexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2008 (NCT00641225)
Timeline
Indications
Mechanism of action
- B-lymphocyte antigen CD20INHIBITOR
MS4A1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- sbi-087
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01008852 | Phase 2 | Dec 1, 2009 | Emergent BioSolutions, Pfizer |
| NCT00714116 | Phase 1 | Feb 1, 2009 | Emergent BioSolutions, Pfizer |
| NCT00815906 | Phase 1 | Dec 1, 2008 | Emergent BioSolutions, Pfizer |
| NCT00641225 | Phase 1 | Mar 1, 2008 | Emergent BioSolutions, Pfizer |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Emergent BioSolutions | For profit | 4 | 0 | 2 | 2008 |
| Pfizer | For profit | 4 | 4 | 2 | 2008 |
2 organizations
Page 1 / 1